Vaccines are one of the most successful medical interventions in human history, saving 2.5 million lives per year and protecting millions more from severe illness and hospitalization, according to the WHO. Despite this incredible success, there are many infectious diseases for which effective vaccines do not currently exist. One strategy to developing new or more protective vaccines is through the addition of adjuvants, which help activate the immune system.

Inimmune is a leader in the discovery and development of vaccine adjuvants with over 20 years of expertise in their safe and effective use. Inimmune’s novel small molecule adjuvants can activate the immune system in specific ways to drive the right immune response to deliver protection against pathogens of interest. Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants. In addition, our formulations team has extensive expertise in tailoring vaccine delivery systems for these innate immune agonists, to match the route of administration and dosing required for a given indication.